News In Brief

Judge rejects Orthofix settlement with feds. ConvaTec purchases catheter-provider 180 Medical. Cook announces new product division. More news briefs.

A trial date has been set for March 11, 2013, in a federal suit against Orthofix Inc., following a judge's rejection of a settlement that had been inked between the bone-growth-stimulator maker and federal attorneys. Orthofix had agreed to pay a $7.8 million fine to settle a guilty plea on the felony count of obstructing a federal audit, but Massachusetts U.S. District Court Judge William G. Young rebuffed the deal, the Massachusetts U.S. Attorney’s office confirmed. The action also may have implications for a $34.2 million civil settlement tied to the same investigation. Federal attorneys say Orthofix engaged in kickbacks and other fraudulent activities in effort to sell and secure reimbursement for its devices. (See Also see "Judge Weighs $42 Million Orthofix Settlement With Feds" - Medtech Insight, 30 July, 2012..) “The company and the government stand behind their agreements and continue to discuss a resolution of the matter following the court’s rejection of the plea,” Orthofix CEO Robert Vaters said.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By 

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

Careology And Entia Partner To ‘Enhance’ Remote Monitoring For Patients With Cancer

 

Careology and Entia are partnering to “alleviate the burden of routine patient assessments” on people with cancer. The two early-stage London-based health tech startups already provide services to UK National Health Service (NHS) patients.

More from Business

Biolinq’s $100M In Series C Financing Supports Efforts To Bring Diabetic Glucose Monitoring With Needle-Free Patch To Market

 
• By 

Biolinq plans to use the proceeds of its new venture funding to support US FDA de novo review, automation engineering and commercialization efforts with partners, CEO Rich Yang told Medtech Insight.

OneCell Diagnostics – Now 1Cell.Ai - Launches Multi-Modal Cancer Diagnostic Panel OncoIncytes

 

OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.

Abbott, J&J Reaffirm 2025 Profit Guidance Despite Growing Tariff Uncertainties

 
• By 

Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.